Research on the biological roles of nitric oxide has revealed that it functions as an important signal and effector molecule in a variety of physiologic and pathologic settings. In animals, nitric oxide is synthesized enzymatically from L-arginine through the actions of the nitric oxide synthases (NOSs). The three known NOS isoforms are all dimeric, bi-domain enzymes that contain iron protoporphyrin IX, flavin adenine dinucleotide, flavin mononucleotide, and tetrahydrobiopterin as bound prosthetic groups. This chapter summarizes information regarding the structure-function aspects of the NOSs, which includes composition of the domains, the protein residues and regions involved in prosthetic group binding, catalytic properties of the domains, the relationship between dimeric structure and prosthetic group binding and function, and factors that control assembly of NOS in cells. A general model for NOS structure and assembly is presented.
INTRODUCTION
Like many enzymes, the nitric oxide synthases (NOSs) have evolved to function in an oligomeric form, i.e. they are only active as dimers comprised of identical subunits. This chapter summarizes research on the structure-function relationships of the three NOS isoforms, specifically addressing the composition and role of each NOS domain and subunit dimeric interactions, how dimerization impacts on active site structure and prosthetic group activity, and the mechanisms by which dimer assembly may be controlled in cells. Readers interested in the biology (1) (2) (3) (4) (5) (6) , enzymology (7) (8) (9) , or transcriptional and 339 0362-1642/97/0415-0339$08.00 translational regulation of NOS (10) are directed to reviews that have appeared in the literature. These topics are not covered in the present chapter. Figure 1 illustrates a general model for the structure and domain composition of an active dimeric NOS, using the cytokine-inducible mouse NOS isoform (iNOS) as an example. It shows two NOS subunits aligned in a head-to-head manner, with the oxygenase domains of each subunit interacting to form the dimer, and the reductase domains attached as independent extensions. Domains, regions within domains, and residues that are thought to participate in binding specific prosthetic groups and substrates are marked. Active dimeric NOSs contain iron protoporpyrin IX (heme), tetrahydrobiopterin (H4biopterin), FAD, and FMN as bound prosthetic groups, and also contain binding sites for L-arginine, calmodulin (CaM), and NADPH. In addition, one isoform [exemplified by rat neuronal NOS (nNOS)] contains a 250-amino acid N-terminal leader sequence that is not present in the other two NOS isoforms. The leader sequence is not required for dimerization, prosthetic group binding, or catalysis of NO synthesis, but it is involved in binding proteins that target nNOS to discrete regions in cells (11) . The evidence that led to the general structural model shown in Figure 1 is discussed below.
General Model of NOS Structure and Composition
consensus binding regions were all located within the carboxyl half of NOS (between amino acid residues 532 and 1144 in the mouse iNOS and homologous regions in the other two isoforms) (see 2, 7-9 for details), making this region of NOS structurally homologous with the dual-flavin enzymes NADPHcytochrome P-450 reductase, the flavoprotein subunit of sulfite reductase, and the C-terminal reductase domain of the bacterial cytochrome P-450 BM3 (reviewed in 16) . Because these proteins all function to transfer electrons derived from NADPH to an endogenous heme group or associated hemeprotein, the C-terminal half of NOS was proposed to function as a reductase domain that transfers electrons from NADPH to another redox component located in a different region of the protein. This redox component was subsequently identifed to be iron protoporphyrin IX (heme) (21) (22) (23) (24) , which resides within a N-terminal oxygenase domain of NOS.
Assignment of the CaM-, flavin-, and NADPH-binding sites within the Cterminal reductase domain and the heme-, H4biopterin-, and L-arginine-binding sites within the N-terminal oxygenase domain of NOS was confirmed through limited proteolysis studies (25, 26) and expression of the individual domains (27) (28) (29) (30) . Point and deletion mutagenesis of iNOS has confirmed the involvement of C-terminal residues 1121-1144 in NADPH binding (31) . Synthetic peptides of 28 to 35 residues that correspond to the putative CaM-binding sites of iNOS and nNOS have been shown to bind CaM with an affinity that matches that of the intact enzymes (32) (33) (34) (35) (36) (37) , confirming their function and indicating that CaM-binding affinity is determined by a relatively small region of NOS. Although sequence differences within the NOS CaM-binding peptides apparently do confer different affinities toward CaM, other regions of NOS may also have a role in the interaction, based on studies with NOS chimeras that were constructed to contain another NOS isoform's CaM-binding sequence (36) or on a study that investigated interactions between nNOS and CaM-troponin c chimeras (38) .
A variety of spectroscopic evidence indicates the NOS heme iron is axially coordinated to the protein by a Cys thiolate (21-24, 30, 39, 40) . Sequence and modeling studies based on other thiolate-ligated hemeproteins such as cytochrome P-450 suggested that the coordinating Cys residue is located within the oxygenase domain at positions 194, 415, and 184 in iNOS, nNOS, and human endothelial NOS (eNOS), respectively (23, 41) . Point mutagenesis of the putative heme-binding Cys residues to Ala or His resulted either in loss of heme binding (42) (43) (44) or formation of an unstable heme-containing species with possible heme axial coordination to a His imidazole nitrogen (27) , all consistent with these Cys residues providing the coordinating thiolate.
Amino acids or regions within the oxygenase domain that are involved in H4biopterin or L-arginine binding have not been clearly identified. Homology matching with other pterin-binding proteins has led to three proposed sites for H4biopterin binding that are all located C-terminal to the heme-binding Cys residue. One region that was proposed to lie within the reductase domain (45) can likely be discounted based on proteolysis and expression studies that show H4biopterin clearly binds in the oxygenase domain (25) (26) (27) (28) (29) (30) . A region in the oxygenase domain (residues 448-480 in iNOS) was noted to be somewhat homologous with the H4biopterin-binding sites in aromatic amino acid hydroxylases (46) . Two relatively conservative point mutations in this region (G450A and A453I in iNOS) led to a loss of both H4biopterin binding and dimeric structure, but retention of heme binding (46) . However, it is difficult to assign a role for residues G450 and A453 in H4biopterin binding at this point, because mutations that disrupt NOS dimer formation may also prevent stable binding of H4biopterin to the protein, as has been observed with native iNOS and nNOS monomers (47, 48) . A related larger region in the oxygenase domain (residues 340-494 in iNOS) has been noted to be similar to the dihydrofolate reductase (DHFR) pterin-binding module (49) . However, experiments with this fragment following its expression as a GST-fusion peptide suggested it could bind radiolabeled nitroarginine but not H4biopterin (49) , suggesting that it may instead participate in L-arginine binding. Point mutagenesis of residues in a region of the oxygenase domain that is N-terminal from the heme-binding site (C99A in eNOS) resulted in a protein with decreased affinity for H4biopterin but otherwise normal characteristics regarding dimeric structure, L-arginine binding, and activity, suggesting that C99 might help modulate H4biopterin-binding affinity (50) . Thus, residues involved in H4biopterin and L-arginine binding reside in the oxygenase domain but may be distributed on opposite sides, or possibly both sides, of the heme binding site.
The findings outlined above identify NOSs as bimodal enzymes comprised of a heme-containing oxygenase domain and a reductase domain that binds CaM, FMN, FAD, and NADPH. A similar bi-domain structure had been described for the bacterial cytochrome P-450 BM3 , which catalyzes the NADPHdependent mixed-function monooxygenation of fatty acids (51) . Thus, NOS prosthetic group function is modeled after flavin and heme function in cytochrome P-450 catalysis (see 7-9 for review). In NOS, the flavins accept electrons from NADPH and transfer them to the heme iron, which is then envisioned to bind and activate oxygen, and to catalyze the stepwise oxidation of L-arginine to NO (Scheme 1). Although this model has been consistent with results to date and thus may explain how the flavins and heme function during NO synthesis, it does not address why NOS requires a dimeric structure and bound H4biopterin to catalyze NO synthesis. These and other issues are discussed below.
THE REDUCTASE AND OXYGENASE DOMAINS OF NOS

Composition and Physical Properties
The oxygenase and reductase domains of an nNOS or iNOS dimer can be cleaved apart by limited trypsinolysis and purified from one another using 2 , 5 ADP sepharose chromatography (25, 26) . In iNOS a single cut is primarily obtained at the junction of the oxygenase domain and CaM-binding site (residue R503), while in nNOS cuts occur both at this point and within the CaM-binding region, and also near the junction of the N-terminal leader sequence and the oxygenase domain. In all cases, trypsin cleavage destroys the ability of the remaining protein fragments to generate NO from L-arginine but does not alter the prosthetic group content or spectral properties of the individual domains, suggesting they remain intact. Indeed, the oxygenase domains so generated are homodimeric, contain H4bioipterin and Cys-ligated heme, and can bind L-arginine, whereas the reductase domains are monomeric, bind NADPH, and contain bound FAD, FMN, and in the case of iNOS, CaM. These studies confirmed a bi-domain structure for NOS, tentatively identified each domain's boundaries, and clarified the prosthetic group content and substrate binding properties of each domain. The main points have since been confirmed by expressing the individual domains in bacteria, yeast, or insect cells (27) (28) (29) . That a dimeric interaction was maintained only by the NOS oxygenase domains after trypsin cleavage was the first indication that the oxygenase domain contains the determinants required for dimerization. This led to a model for NOS dimeric structure, shown in Figure 1 , in which the subunits align in a head-to-head manner, with the oxygenase domains interacting to form the dimer, and the reductase domains attached as independent extensions (26) . This model is consistent with light-scattering studies showing that dimeric nNOS has an elongated structure (52) . A similar arrangement has been proposed for other multi-domain dimeric enzymes such as spinach nitrate reductase (53) and rat liver sulfite oxidase (54) . Both enzymes are comprised of a molybdenum-containing catalytic domain that possesses the determinants for maintaining dimeric structure, while associated domains that shuttle electrons through the enzyme remain monomeric. Thus, the NOSs may belong to a family of multi-domain redox enzymes whose subunit interactions follow this general pattern. However, the data on which Figure 1 is based do not exclude the NOS reductase domain from influencing subunit dimeric interactions, as has been suggested for eNOS based on an immunoprecipitation study with cells coexpressing the full-length enzyme and a truncation construct that contains only the eNOS reductase domain (55) . In that study, overexpression of a reductase domain fragment prevented eNOS homodimer formation in cells and apparently led to the generation of a nonfunctional heterodimer comprised of a full-length subunit attached to a reductase domain fragment. Further work is required to determine whether the reductase domain can participate in dimeric interactions of eNOS under normal expression conditions.
Oxygenase Domain Active Site
A number of studies have investigated how substrate and H4biopterin affect heme iron ligand structure and electronic properties in NOS, using in some cases the isolated oxygenase domains or in others the full-length enzymes. In the absence of both H4biopterin and L-arginine, the ferric heme iron of NOS is predominantly six-coordinate low spin (27, (56) (57) (58) (59) (60) . Binding of H4biopterin or L-arginine favors the five-coordinate high spin form of the NOS heme iron, with H4biopterin binding alone producing a mixture of the two spin states, and L-arginine binding alone resulting in an almost a complete shift to high spin (27, (56) (57) (58) (59) (60) . Investigations of L-arginine or L-arginine analog binding to the H4biopterin-containing ferric NOS suggests that several distinguishable binding modes can occur (30, 61, 62) . Studies using various inhibitors suggest that the NOS isoforms differ regarding the geometry of their substrate binding pockets (reviewed in 3, 7). Both H4biopterin and L-arginine appear to bind near the distal side of the heme and can influence each other's binding (63) . Bound L-arginine and H4biopterin also influence the binding of heme iron ligands-such as NO, CO, CN − , and imidazole to both ferric and ferrous NOS (39, 64-66)-and can shield distinct portions of the porphyrin macrocycle from alkylating agents generated within the active site (67) . These effects were somewhat expected for L-arginine based on mechanistic considerations and a similarity between NOS and the cytochromes P-450 (39, 64-67), but they were surprising for H4biopterin and suggest a new role for this molecule with respect to hemeproteins. Investigating how H4biopterin influences heme iron reactivity and active site structure may help us understand how it participates in NO synthesis. Also, continued work may reveal if the heme environments in the full-length and oxygenase domain versions of a given NOS isoform differ from one another, and thus indicate whether attached reductase domains have a role in modulating active site structure.
Catalytic Properties of the Isolated Domains
The reductase domains of each NOS isoform (including attached CaM-binding sites) have been generated either by proteolysis of the full-length enzyme or by expression in bacteria, yeast, and insect cells (25) (26) (27) (28) (29) . In general, the reductase domains catalyze electron transfer from NADPH to acceptors such as cytochrome c and ferricyanide at rates that match those obtained with the respective full-length NOS dimers or monomers. CaM binding to the eNOS or nNOS reductase domains also stimulates their electron transfer to cytochrome c by the same magnitude as in the full-length enzymes (28, 29) . This suggests that CaM's effect on reductase activities is due to its interaction with reductase domain alone and does not require or involve the NOS oxygenase domain. The NOS reductase domains are very slow to transfer electrons to dissolved O 2 in both the CaM-free and CaM-bound states (26, 28, 29, 47) , making them poor superoxide generators. This is consistent with superoxide production by full-length NOS in the absence of L-arginine requiring electron transfer to the heme iron and arising through heme-catalyzed electron transfer to dioxygen (reviewed in 7).
Forms of the nNOS reductase domain that are missing a functional CaMbinding site catalyze cytochrome c or FeCN6 reduction at rates that exceed those of the intact CaM-free reductase domain (27, 28) . Thus, the CaM-binding peptide is not required for electron transfer to these acceptors and might actually be autoinhibitory in the absence of bound CaM. Further work may determine if the NOS CaM-binding peptide can also influence electron transfer between the reductase and oxygenase domains of NOS in a similar manner.
The iNOS oxygenase domain dimer cannot catalyze NO synthesis when supplied with NADPH, H4biopterin, O 2 , and substrate. However, it can convert the reaction intermediate N ω -hydroxy-L-arginine (L-NOHA) to NO and citrulline in the presence of H 2 O 2 (N Sennequier & DJ Stuehr, unpublished observations), consistent with H 2 O 2 also supporting L-NOHA oxidation by the full-length iNOS dimer in the presence of H4biopterin (69) . That the iNOS oxygenase domain can catalyze the second step in NO synthesis using H 2 O 2 as a source of reduced oxygen indicates that it maintains at least this portion of its catalytic function. Thus, the oxygenase and reductase domains of NOS appear to be catalytically active independent of one another when provided with suitable conditions.
Catalysis in a Mixed-Domain System
Mixtures of purified iNOS reductase and oxygenase domains can catalyze NADPH-dependent oxidation of L-NOHA to form NO and citrulline (70) , while an eNOS mixed-domain system can support oxidation of both L-arginine and L-NOHA to NO and citrulline (29) . For either isoform, the maximal rates obtained in the mixed domain system (on a per heme basis) were significantly less than the intact enzymes. For eNOS, the activity in the mixed-domain system required bound CaM, implying that electron transfer between separate domains in solution may also be CaM dependent, although this was not directly tested. For iNOS, the maximum specific activity in the reconstituted system was obtained at an oxygenase-to-reductase domain molar ratio of 4:1, whereas for eNOS the situation was reversed in that excess reductase domain was optimal. Studies in the iNOS system indicated that the reductase domain transfers electrons from NADPH to the dimeric oxygenase domain, but this only led to reduction of 25% of the available oxygenase domain heme iron in the presence of CO, which is far below the ∼95% heme reduction obtained with substrate-bound, full-length dimeric iNOS under identical conditions (71, 72) . Additional study showed that most of the NADPH oxidation that occurred in the mixed-domain system was uncoupled to heme iron reduction. This suggests that the separated NOS reductase and oxygenase domains can only interact suboptimally in solution to catalyze NO synthesis. Electron transfer between the separate domains is inefficient and probably represents a limiting factor for NO synthesis, which requires a sequential transfer of three electrons between the reductase and oxygenase domains to convert L-arginine to citrulline and NO (7-9).
DISSOCIATION AND UNFOLDING OF DIMERIC NOS AND ITS DOMAINS
Dissociation and unfolding transitions of full-length dimeric iNOS (73) have been studied using urea as a denaturant. In the case of the full-length enzyme, dimer dissociation and subunit unfolding each occur as separate transitions in defined concentration ranges of urea, with each transition being accompanied by the loss of a specific catalytic function (Figure 2 ). Dimer dissociation occurs between 0 and 2.5 M urea and produces an increasing population of folded monomers that are devoid of bound H4biopterin but still contain bound heme, FAD, FMN, and CaM. These monomers are inactive regarding NO synthesis but express full cytochrome c or ferricyanide reductase activities. At urea concentrations above 2.5 M, the iNOS monomer partially unfolds, as judged by an increase in its hydrodynamic volume and loss of reductase activities. Thus, loss of NO synthesis and reductase activities can each serve to indicate the dissociation and unfolding transitions of dimeric iNOS, respectively.
Dissociation of the iNOS dimer disables electron transfer between the reductase domain and the oxygenase domain heme iron (74) . Specifically, hemecontaining monomers that are provided with NADPH can reduce their flavins but can no longer transfer the electrons to the heme iron, even in the presence of CO. This may be related to the heme iron converting to low spin upon dimer dissociation. A lack of heme iron reduction likely explanains why the monomers cannot catalyze NO synthesis and suggests a novel role for dimerization in controlling electron transfer within iNOS.
A similar study with nNOS dimer showed that its dissociation required higher concentrations of urea (HM Abu-Soud & DJ Stuehr, unpublished results). As a Figure 2 Model for urea-promoted dissociation and unfolding of dimeric iNOS. Subunit dissociation and unfolding occur within two distinct urea concentration ranges. The first transition involves a dissociation between the oxygenase domains of two interacting subunits. This is accompanied by a loss of NO synthesis activity and release of bound H4biopterin (H 4 B), but retention of the cysteine thiolate-ligated heme, flavins, CaM, and full reductase activities. The sixth coordination position of the heme iron becomes exposed to solvent during subunit dissociation. The unfolding transition (iNOS*) is associated with a loss of reductase activities and partial release of bound heme, but retention of bound flavins and CaM. The dissociated, folded subunits can reform an active dimer in the presence of added H4biopterin and L-arginine. However, the loss of reductase activities associated with the unfolding transition can only be partially reversed.
consequence, the dissociation and unfolding transitions for this isoform exhibit considerable overlap and a very small population of folded monomers can be obtained. Thus, the nNOS dimeric interaction appears to be more stable toward urea than is the iNOS dimeric reaction. Further investigation should reveal if NOS isoform stability toward denaturants reflects differences in their primary sequences.
Urea-promoted dissociation and unfolding transitions of the individual oxygenase and reductase domains of iNOS have also been studied (76) . As with full-length iNOS, urea treatment dissociates the oxygenase domain dimer into folded, heme-containing monomers. However, the concentration of urea required to dissociate the oxygenase domain dimer is considerably higher than that required to dissociate the full-length iNOS dimer (76) . This suggests that attached reductase domains may destabilize the dimeric interaction formed between two oxygenase domains. A destabilizing effect is consistent with the structural model of Figure 1 , in which the reductase domains are attached as monomeric extensions to a dimeric oxygenase core.
Unlike full-length iNOS, an unfolding transition for the isolated oxygenase domain was not observed even at 5 M urea. However, the isolated iNOS reductase domain unfolded in response to urea at concentrations that were identical to those that caused full-length iNOS to unfold (73, 76) . This indicates that the two domains of iNOS differ regarding stability toward urea. The relative instability of the reductase domain likely explains why full-length iNOS unfolds at high urea concentrations but the isolated oxygenase domain does not.
Dissociation of the iNOS oxygenase domain dimer is accompanied by an increase in protein tryptophan fluorescence (76) . Spectral analysis of the dissociation reaction also showed that the heme iron converts to a fully low-spin configuration, presumably due to its binding water or hydroxide ion as a sixth ligand. In addition, other soluble heme iron ligands, such as DTT, that are too bulky to bind to the H4biopterin-containing dimer are able to bind to the monomer heme iron and form a bis-thiolate complex (73, 76) . These results indicate that the sixth coordination site of the heme iron becomes exposed to solvent when the dimer dissociates into monomers. However, it was not determined whether exposure of the distal heme pocket was caused by dimer dissociation or by loss of bound H4biopterin during dissociation. This issue has been clarified upon examining H4biopterin-free NOSs expressed in bacteria (27, (56) (57) (58) (59) (60) 62) , which contain fully low-spin heme iron and can bind DTT as a sixth ligand in spite of existing in dimeric form. Thus, inclusion of H4biopterin into the protein and not dimerization per se seems to limit solvent and ligand accessibility to the distal heme pocket.
FORMING AND STABILIZING THE NOS DIMER: ROLES FOR PROSTHETIC GROUPS AND SUBSTRATE
Studies have been carried out with purified heme-free iNOS and nNOS monomers isolated from mammalian cells (47, 48) , with heme-containing monomers generated by dissociating full-length dimeric iNOS or the iNOS oxygenase domain with urea (73, 76) , and with heme-containing, H4biopterin-deficient nNOS and eNOS dimers (52, 58) .
Heme-Free NOS Monomers
Monomers of iNOS and nNOS that are devoid of bound heme and H4biopterin can be isolated from mammalian cells (47, 48) . In the case of nNOS, the heme deficiency results from poor heme biosynthesis within insect cells (48) , whereas for iNOS it may arise from a defect in heme insertion (see section below). Circular dichroism with the heme-free nNOS monomer indicates that its secondary structure is very similar to that of the dimeric enzyme (48) . The heme-free monomers contain normal amounts of FAD and FMN, a functional CaM-binding site, and bound CaM (iNOS only). They cannot generate NO from L-arginine but function equivalent to their dimeric enzymes in catalyzing NADPH-dependent reduction of electron acceptors such as cytochrome c, ferricyanide, and dichlorophenolindophenol. Thus, folded heme-free NOS monomers that contain functioning reductase domains can exist in cells and may represent an intermediate in the path of dimerization.
An important property of iNOS and nNOS heme-free monomers is that they are unable to stably incorporate H4biopterin (47, 48) . This differentiates them from H4biopterin-free NOS dimers, in which H4biopterin once bound exhibits a very slow dissociation from the protein (63) . The nNOS monomers are also unable to bind the substrate analog nitroarginine, which binds tightly with slow dissociation to the nNOS dimer (63) . The inability of the full-length nNOS monomer to bind nitroarginine contrasts with the apparent ability of a heme-free fragment of the nNOS oxygenase domain (residues 558-721) to bind nitroarginine (49) . Further work may clarify this discrepancy. Also, it should be noted that these studies have employed a filter binding assay and thus might not detect binding events that approach equilibrium quickly.
Dimerization of heme-free NOS monomers has been investigated with iNOS and nNOS. Purified NOS monomers do not reassociate into a dimer when incubated together at micromolar concentrations in a minimal buffer. However, dimerization of iNOS nomomers is promoted in the coincident presence of L-arginine, H4biopterin, and a stoichiometric amount of heme (47) . Omission of any one of the three molecules that promote dimer assembly either reduced (H4biopterin) or prevented (heme, L-arginine) iNOS dimer assembly. Curiously, significant dimerization of heme-free nNOS monomers was obtained upon addition of heme alone (48) , suggesting that heme insertion may be the major factor that promotes dimer assembly in this isoform.
Dimer formation in the iNOS system was accompanied by incorporation of stoichiometric amounts of heme and near-stoichiometric amounts of H4bio-pterin into the protein and a proportional reconstitution of NO synthesis activity (47) . The heme iron in the reconstituted dimer was ligated to the protein through a cysteine thiolate, and the dimer expressed a specific activity similar to native dimeric iNOS. This indicates that the prosthetic groups bound properly in the monomers during dimerization. The kinetics of iNOS dimer reconstitution suggest that dimer formation in this system is relatively slow, taking 60-120 min to approach completion at 37
• C. Comparable kinetic, structural, and catalytic measurements on heme-promoted nNOS dimer assembly are awaited with interest.
The above studies showed that heme and possibly H4biopterin and L-arginine could regulate NOS dimeric structure, identifying new roles for these molecules that are independent of their function in catalysis. Although substrate or prosthetic group affects on enzyme subunit assembly is well documented (reviewed in 77), the possible involvement of two prosthetic groups (heme, H4biopterin) and substrate (L-arginine) is unusual and suggests multiple means by which NOS dimer assembly can be regulated in cells (discussed in a later section for iNOS).
Heme-Containing Monomers
Studies with heme-containing monomers generated from full-length iNOS or its oxygenase domain showed that they also can reassociate to form a dimer in the presence of added L-arginine and H4biopterin (76) . In this system, dimerization was substantial when either L-arginine or H4biopterin were added alone, but was maximal with addition of both. Exogenous heme was not required to promote dimer assembly and actually inhibited the process, consistent with heme being already incorporated within the protein. Dimer formation was associated with a proportional recovery of NO synthesis (for full-length subunits only), a decrease in oxygenase domain tryptophan fluorescence, and recovery of the original spectral characteristics of the heme iron. The time course of dimer assembly was similar to that seen with heme-free iNOS monomers. This work suggests that the oxygenase domain of iNOS contains all of the determinants required for subunit dimerization, ruling out an obligatory role for the reductase domain in this process. The changes in heme catalytic function and electronic environment that occur during urea-promoted dimer dissociation are reversed during L-arginine-and H4biopterin-promoted dimer reassembly, indicating that the changes are reversible.
Two studies have investigated a role for H4biopterin in stabilizing nNOS and eNOS dimeric structure. Binding of H4biopterin to purified dimeric nNOS strengthens the subunit interaction such that the dimers become resistant to dissociation in 2% SDS (52) . However, a similar stabilizing effect for H4biopterin was not seen with eNOS monomers and dimers expressed in bacteria and subsequently exposed to 0.1% SDS (58) . In that study, the eNOS dimers remained stable toward SDS in the absence of H4biopterin, and added H4biopterin did not promote monomers to form stable dimers. Although the capacity of H4biopterin to promote dimer formation might depend on the heme content of the eNOS monomers, this was not specifically determined. Further work is expected to clarify the relative importance of H4biopterin in promoting and stabilizing the dimeric structure of the three NOS isoforms.
Promoting Dimer Assembly with L-Arginine Analogs
A variety of L-arginine and guanidine analogs were shown to promote dimerization of heme-containing, full-length iNOS monomers in the presence of H4biopterin (78) . Their capacity to promote dimer assembly correlated with their ability to bind to dimeric iNOS, which in the absence of NO synthesis was detected and quantitated by monitoring the analog-dependent shift in heme iron spin equilibrium and/or change in dimeric iNOS NADPH oxidase activity. In all cases, newly formed dimers could catalyze NO synthesis when assayed in the presence of L-arginine.
Dimer formation was also promoted by analogs of guanidine and thiourea, indicating that the amino acid portion of L-arginine is not essential. Some analogs (hydroxyguanidine, S-ethylisothiourea) consistently promoted greater dimerization than the maximal value obtained with L-arginine itself. Several promoted less dimerization than L-arginine, in most cases because of poor binding affinity. Of the analogs that did not promote dimerization, only two (thiocitrulline and N ω -aminoarginine) displayed high binding affinity toward dimeric iNOS. In sum, a given analog's capacity to promote dimerization was independent of its functioning as a substrate, its causing a high or low spin shift, or its up-or down-regulating iNOS NADPH oxidase activity. Occupancy of the substrate binding site promoted iNOS dimerization, suggesting that this is the primary means by which L-arginine exerts its effect.
Investigating the Dimeric Interaction with NOS Heterodimers
Coexpressing iNOS mutants in mammalian cells has revealed that a number of mutants can complement each other by forming heterodimers amongst themselves (43, 46, 55) . These include mutants that do not bind heme or form a homodimer (C194A), do not form a homodimer in spite of binding heme (C194A, G450A, A453I), do not bind NADPH, or are missing most of the reductase domain. The activity and composition of the heterodimers was determined by techniques that did not require the proteins to be purified from the cell lysates. These studies indicated that iNOS heterodimer formation is relatively insensitive to single mutations in the oxygenase domain and to mutations or deletions of the reductase domain. For example, the homodimer-negative mutants C194A, G450A, and A453I all formed heterodimers with mutants that contained wild-type oxygenase domains. C194A also dimerized to some extent with the G450A mutant. Analysis for NO synthesis activity suggested that iNOS heterodimers containing only one functional reductase domain were active, but those containing only a single heme were not (43) . The authors proposed that the second heme may help maintain the structure of the other chain's independently functioning active site, or could alternatively participate in the functioning of a single common active site.
An iNOS heterodimer containing two oxygenase and one reductase domain has been generated in sufficient quantities to enable purification and study regarding its catalysis and electron transfer functions (74) . The heterodimer synthesized NO from L-arginine, confirming that only one reductase domain need be present. However, the heterodimer differed from a normal full-length iNOS homodimer in two ways. It synthesized NO at a rate that was half maximal with respect to a full-length homodimer. Also, only half of the available heme iron in the heterodimer was subject to reduction by NADPH, in contrast to the full heme reduction normally obtained in a full-length iNOS homodimer. The authors proposed that the single reductase domain can transfer electrons to only one of the two hemes, and this single heme is capable of catalyzing NO synthesis from L-arginine at a normal rate. This model is consistent with each heme functioning independently in the dimer, rather than both hemes participating as a single active site. Further work should reveal how electrons transfer from the single reductase domain to an individual heme and identify which of the two hemes is the electron acceptor. It will also be important to determine whether electrons can transfer between reductase domains in a full-length iNOS homodimer prior to reaching the oxygenase domain heme irons. In general, further complimentation analysis and work with purified heterodimers should help to understand structure-function aspects of dimerization and catalysis.
CELLULAR CONTROL OF INOS DIMER ASSEMBLY
Role for H4biopterin
Indications that heme and possibly L-arginine and H4biopterin promote NOS dimer assembly and stabilization in vitro have led investigators to address whether these molecules also have a role in controlling NOS dimer assembly in cells. The relative importance of H4biopterin in promoting NOS dimer formation in cells is controversial. The generation of dimeric, H4biopterin-free NOS isoforms in Escherichia coli expression systems (56) (57) (58) (59) (60) 67) argues that H4biopterin is not absolutely required to dimerize NOSs when they are being overexpressed in prokaryotes. A similar finding was reported for iNOS expressed in mouse smooth muscle cells that were grown in the presence of a H4biopterin biosynthesis inhibitor (79) . On the other hand, expression of dimeric human iNOS in NIH3T3 cells, which have no capacity for endogenous H4biopterin biosysthesis, was minimal (dimers represented <25% of the total iNOS protein) unless exogenous H4biopterin or a biosynthetic precursor (sepiapterin) was supplied to the culture medium (80) . Thus, the degree to which H4biopterin is required for dimer assembly in cells may depend on the isoform and the expression system under study. Whether L-arginine levels can limit intracellular NOS assembly has not been fully investigated. Insufficient heme biosynthesis in insect cells has been proposed to limit heme insertion into nNOS and may prevent its dimerization (48, (81) (82) (83) .
Control of iNOS Dimer Assembly in Cytokine-Activated Cells
Previous studies indicate that iNOS is expressed in cytokine-activated cells as a mixture of dimer and monomer (47) , implying that either the dimer is unstable or its assembly is limited. A recent report has examined these issues by addressing whether availability of L-arginine, H4biopterin, or heme influence cellular assembly of the iNOS dimer (84) . In a cytokine-activated macrophage cell line, total iNOS protein (monomer plus dimer) was observable by 2 h and accumulated in a near-linear manner through 16 h of culture. However, the rate at which the iNOS dimer accumulated fell over time such that beyond 10 h almost no additional dimer accumulated, and by 16 h only 25% of the total iNOS protein was in dimeric form.
Experiments with the protein synthesis inhibitor cycloheximide indicated that the iNOS dimer was stable in the macrophage cells for at least 8 h, suggesting that a time-dependent defect in dimer assembly arises during the cell culture. Further work argued against L-arginine or H4biopterin availability limiting iNOS dimer assembly. Addition of extra L-arginine to the cell cultures did not increase cellular dimer accumulation, and intracellular H4biopterin levels were shown to increase fourfold during the culture period, consistent with cytokine coinduction of H4biopterin biosynthesis (85, 86) . However, blocking cellular NO synthesis with NOS inhibitors greatly increased iNOS dimer assembly, indicating NO synthesis somehow limits iNOS dimerization. NO synthesis also prevented an increase in cellular heme level that was obtained in response to cytokines in cells that were given NO synthesis inhibitors. Addition of the porphyrin precursor δ-aminolevulinic acid or hemin to the NO-producing cells elevated their intracellular porphyrin and heme levels, respectively, but did not increase incorporation of heme into iNOS or promote additional dimer assembly.
These findings suggest that a substantial, time-dependent defect in iNOS dimer assembly and heme utilization arises in cells because of their own NO synthesis. The authors (84) proposed three potential mechanisms by which selfgenerated NO could limit iNOS dimer assembly. First, NO synthesis appears to prevent accumulation of cellular heme that otherwise occurs in cytokineactivated cells in the presence of an NO synthesis inhibitor. A mechanism by which NO could limit accumulation of intracellular heme is through inactivating ferrochelatase, which inserts iron into the porphyrin ring (87) . Ferrochelatase contains an iron-sulfur center that can be inactivated by reagent NO, and cellular ferrochelatase activity is inhibited in a time-dependent manner during NO synthesis in cytokine-activated cells (88) . A second mechanism may involve NO-mediated iron release from cells (89) , which through activating iron response elements leads to repression of δ-aminolevulinate synthase (90), the rate limiting enzyme in heme biosynthesis. Finally, the fact that iNOS dimer assembly was not increased even when heme biosynthetic enzymes were bypassed (i.e. by adding hemin to cells generating NO and increasing their intracellular heme level) suggests that NO may directly prevent heme insertion into the iNOS protein. An ability of NO to antagonize heme insertion into NOS may be related to its capacity to inactivate cytochrome P-450 hemeproteins in a variety of biological systems (91) (92) (93) and may help explain how NO limits NO synthesis in cells expressing iNOS (94) .
CONCLUSIONS AND PERSPECTIVE
A model for assembly of an active NOS that is based on the available evidence is shown in Figure 3 . Active NOS may assemble in two sequential posttranslational steps that each involve a separate domain of the enzyme. The protein first aquires a functional reductase domain by binding FAD, FMN, and in the case of iNOS (95), CaM. This generates a folded NOS monomer that is capable of catalyzing electron transfer from NADPH but is inactive regarding NO synthesis. The monomers then assemble into a dimer in a reaction that requires sufficient heme to be present and may be promoted by the presence of L-arginine and H4biopterin. Insertion of heme forms a heme-containing monomer as a presumed intermediate [evidence has been presented in only one case (82) ]. Dimer formation is accompanied by stable incorporation of H4biopterin into the protein when present, with maximal incorporation thought to be one H4biopterin per subunit (7, 8) . The dimeric interaction likely involves only the oxygenase domains of either subunit, and the reductase domains may be attached as independent monomeric extensions. Dimer assembly in the presence of H4biopterin and L-arginine alters the heme environment and enables electron transfer to occur between the reductase and oxygenase domains (74) , consistent with aquisition of NO synthesis activity. Assembly of NOS dimers in cells may be limited by a negative feedback loop involving NO synthesis. NO could limit heme availability by directly inhibiting ferrochelatase, by downregulating δ-aminolevulinate synthase expression due to NO-mediated depletion of intracellular iron, and by directly preventing insertion of heme into the NOS monomer.
In addition to the fascinating implications dimer assembly has regarding NOS structure-function, it identifies a potential therapeutic strategy for regulating NO synthesis independent of substrate-based competitive inhibitors. It will be interesting to see if guanidine-, pterin-, or imidazole-based antagonists can be developed that enhance or prevent NOS dimer assembly in cells or that can dissociate the dimer once it has formed.
